Finally, a practical implication of the second observation is that therapeutic targeting of either ST2 alone or IL-9 alone in human patients with pulmonary fibrosis may be less efficient than simultaneous targeting of these two factors, e.g., with a bispecific neutralizing antibody. This evidence concerns the gene IL9 and pulmonary fibrosis.